Showing results (301-310 of 383) with videos related to

Sort By:
Pageof 39
Fetal Diagnosis and Therapy|March 8, 2000
Severe oligohydramnios with intact membranes: an indication for diagnostic amnioinfusionP G Pryde, M Hallak, M R Lauria, et al.
Fetal Diagnosis and Therapy|March 1, 1995
In utero fetal muscle biopsy alters diagnosis and carrier risks in Duchenne and Becker muscular dystrophyM I Evans, E L Krivchenia, M P Johnson, et al.
Molecular Human Reproduction|November 7, 2006
Identification of two novel quantitative trait loci for pre-eclampsia susceptibility on chromosomes 5q and 13q using a variance components-based linkage approachM P Johnson, E Fitzpatrick, T D Dyer, et al.
American Journal of Medical Genetics|February 25, 1998
Combination of elevated maternal serum alpha-fetoprotein (MSAFP) and low estriol is highly predictive of anencephalyY Yaron, D D Hamby, J E O'Brien, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|November 2, 2004
Fetal head biometry following in-utero repair of myelomeningoceleE Danzer, M P Johnson, R D Wilson, et al.
American Journal of Obstetrics and Gynecology|May 18, 1999
Multifetal pregnancy reductions of triplets to twins: comparison with nonreduced triplets and twinsY Yaron, P K Bryant-Greenwood, N Dave, et al.
Fetal Diagnosis and Therapy|January 1, 1997
Use of urinary beta-2-microglobulin to predict severe renal damage in fetal obstructive uropathyA L Freedman, T P Bukowski, C A Smith, et al.
American Journal of Obstetrics and Gynecology|October 1, 1996
Faint and positive amniotic fluid acetylcholinesterase with a normal sonogramC L Brown, K A Colden, R F Hume, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
DOI and alpha-methylserotonin: comparative vascular and nonvascular smooth muscle effects and central 5-hydroxytryptamine2 receptor affinitiesM L Cohen, M P Johnson, K W Schenck, et al.
American Journal of Medical Genetics|February 2, 1996
Parental decisions to terminate/continue following abnormal cytogenetic prenatal diagnosis: "what" is still more important than "when"M I Evans, M A Sobiecki, E L Krivchenia, et al.
Pageof 39